Pharmaceutical executives challenges

The Transformation Challenges Facing Pharmaceutical Executives

Pharmaceutical companies across the globe face unprecedented challenges as revenue streams come under pressure. This is a consequence of pricing pressures caused by healthcare reforms and government austerity measures. At the same time, companies face increased competition and the difficulty of bringing new drugs and products to market. They have to embrace technological innovation and look at cross-industry best practices …

Download ebook: Your Patent Expiry Update – 2014 and beyond

Patent expiry has increasingly proved problematic for the Pharma industry. Whilst blockbuster drugs lose their patent protection and companies suffer losses in brand spending, generics steal the market with cheap, accessible, copycat alternatives.  While products worth $66 billion will lose protection in 2015, companies grasp on to their patents insisting they promise innovation and aid invention. The debate over the …

Sanofi files cases against Glenmark on patent infringement

Sanofi filed a patent infringement petition against Glenmark on their cardiac drug Multaq in the district court of Delaware. They filed the suit against Glenmark and Actavis wanting to prevent them from commercializing its ANDA productprior to the expiration of certain US patents. Multaq is an anti-arrhythmic drug that reduces the risk of hospitalisation for atrial fibrillation (AF) in patients …

Big pharma suffers as patents expire… but great opportunities for generics companies

As recently reported in the Nature News Blog, pharma companies are suffering as some of their best-selling products continue to fall off the "patent cliff". Astra Zeneca reported a 15% drop in revenue in Q3 of 2012, which was blamed primarily on expiring patents by the company's Chief Executive Pascal Soriot. Similarly, Sanofi reported that sales were down by 3.1% …